Radiopharm Theranostics (RADX) Retained Earnings (2024 - 2025)
Radiopharm Theranostics (RADX) has disclosed Retained Earnings for 2 consecutive years, with $13.1 million as the latest value for Q2 2025.
- On a quarterly basis, Retained Earnings fell 65.42% to $13.1 million in Q2 2025 year-over-year; TTM through Jun 2025 was $13.1 million, a 65.42% decrease, with the full-year FY2025 number at $13.1 million, down 65.42% from a year prior.
- Retained Earnings was $13.1 million for Q2 2025 at Radiopharm Theranostics, down from $37.9 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $37.9 million in Q2 2024 to a low of $13.1 million in Q2 2025.